Eli Lilly’s olomorasib gets FDA breakthrough therapy status for pancreatic cancer (LLY:NYSE)
· seekingalpha.com
Eli Lilly’s olomorasib wins FDA breakthrough therapy designation for KRAS G12C pancreatic cancer after prior treatment.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...